Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/8/17 → 2/7/21 |
Funding
- Merck Sharp and Cohme Corporation: $10,850.00
A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants
- Rupp, Richard (PI)
Project: Research project